Compass Therapeutics chief accounting officer Neil Lerner reports $5,900 common share acquisition
CMPX•Neil Lerner, Compass Therapeutics’ chief accounting officer, purchased 10,000 common shares at $0.59 each, bringing his direct beneficial ownership to 430,000 shares.




